Halozyme director sells shares after option exercise
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan reported an exercise-and-sale transaction in company stock.
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan reported an exercise-and-sale transaction in company stock. He exercised options to acquire 7,304 shares of common stock at $38.46 per share, then sold 7,304 shares in an open-market transaction at $75.00 per share.
After these transactions, he holds 14,462 common shares directly and 1,500 options to purchase common stock. The filing states the option exercise and related sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026, indicating the timing was set in advance.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,304 shares ($267K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Krishnan Mahesh
Role
Director
Sold
7,304 shs ($548K)
Approx. gross sale proceeds
$548K
Approx. exercise cost
$281K
Approx. pre-tax spread
$267K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 7,304 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,304 | $38.46 | $281K |
| Sale | Common Stock | 7,304 | $75.00 | $548K |
Holdings After Transaction:
Option to Purchase Common Stock — 1,500 contracts (Direct);
Common Stock — 14,462 shares (Direct)
Footnotes (2)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1.
- F2. Grant to Reporting Person of options exercisable as of April 25, 2025.
Key Figures
Shares sold: 7,304 shares
Sale price: $75.00 per share
Options exercised: 7,304 options
+5 more
8 metrics
Shares sold
7,304 shares
Open-market sale of common stock
Sale price
$75.00 per share
Price for common stock sale on June 29, 2026
Options exercised
7,304 options
Options exercised into common stock at $38.46
Option exercise price
$38.46 per share
Exercise price for options to purchase common stock
Shares held after
14,462 shares
Direct common stock holdings following transactions
Options remaining
1,500 options
Options to purchase common stock outstanding after exercise
Rule 10b5-1 plan adoption date
March 19, 2026
Date trading plan was adopted for these transactions
Option expiration
April 25, 2034
Expiration date for the option grant after partial exercise
Key Terms
Rule 10b5-1, open-market sale, derivative security, Option to Purchase Common Stock, +1 more
5 terms
Rule 10b5-1 regulatory
"made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
open-market sale financial
"transaction_action: "open-market sale" for 7,304 shares of Common Stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for the option"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Option to Purchase Common Stock financial
"security_title: "Option to Purchase Common Stock" for the derivative transaction"
exercise or conversion financial
"transaction_action: "derivative exercise/conversion" associated with code M transactions"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HALOZYME (HALO) director Mahesh Krishnan report in this Form 4?
He reported an option exercise and related sale of Halozyme stock. He exercised options for 7,304 common shares at $38.46, then sold 7,304 shares at $75.00 in an open-market transaction executed the same day.
What option exercise did Mahesh Krishnan report for HALOZYME (HALO)?
He exercised options to purchase 7,304 shares of Halozyme common stock at an exercise price of $38.46 per share. These options were part of a grant that became exercisable as of April 25, 2025, according to the filing footnote.
Was Mahesh Krishnan’s HALOZYME (HALO) trade part of a Rule 10b5-1 plan?
Yes. The filing states the option exercises and sales were made under a written trading plan adopted on March 19, 2026, in accordance with Rule 10b5-1. Such plans pre-schedule trades, reducing the significance of trade timing.
What type of security did Mahesh Krishnan exercise for HALOZYME (HALO)?
He exercised an option to purchase common stock, a derivative security giving the right to buy Halozyme shares at a fixed price. After exercising 7,304 underlying shares, 1,500 options remained outstanding with an expiration date in 2034.
AI-generated analysis. How Rhea-AI works. Not financial advice.
